BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, January 27, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 1999

View Archived Issues

Pharmacopeia to provide lead discovery services to Roche Bioscience

Read More

Abelcet approved in Belgium

Read More

Repligen receives SBIR grants to support discovery of novel active compounds

Read More

Atairgin and Northwestern University to collaborate on ovarian cancer diagnostic

Read More

Corvas enters rNAPc2 manufacturing agreement in anticipation of phase III trials

Read More

Synsorb Biotech's second quarter marked by progress in clinical trials

Read More

Alcon introduces ocular antiinflammatory agent in Germany

Read More

Hoechst Marion Roussel establishes three high-priority compounds during Q2 1999

Read More

Nabi reports positive interim results from Nabi-StaphVAX pivotal trial

Read More

Aradigm presents data on morphine electronic inhaler at pain congress in Vienna

Read More

Highly stable and lipophilic camptothecin derivatives prepared at Tigen

Read More

Ferriprox approved in Europe as second-line thalassemia therapy

Read More

The aging heart: Should we refine management?

Read More

Clinical candidate selected from 5-ht6 receptor antagonist program at Roche

Read More

ACS news flash: Agouron investigates CDK inhibitors as anticancer agents

Read More

Australian academic-industrial team identifies improved opioid analgesics

Read More

General Hospital Corp. discloses DNA vaccine for preventing, treating hepatitis C

Read More

Fujisawa prepares novel series of vasopressin antagonists

Read More

More selective GABA-A receptor ligands prepared and evaluated at Merck & Co.

Read More

University of Minnesota team describes potent and selective kappa-opioid antagonist at ACS

Read More

Institute for Diabetes Discovery researchers synthesize an improved aldose reductase inhibitor

Read More

Temodal approved in E.U. for treatment of recurrent anaplastic astrocytoma

Read More

Cell Pathways seeks approval of Aptosyn in the U.S.

Read More

ACS presentation for PD-176078, a novel calcium channel blocker with analgesic activity

Read More

Double prodrug UR-3216, a potent, long-lasting and orally active gpIIb/IIIa antagonist

Read More

SR-123781A, a novel heparin mimetic with advantages over standard heparin

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 26, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 23, 2026.
  • DNA mutations or genetic disorder concept art

    Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

    BioWorld Science

    Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

  • Illustration of human body surrounded by DNA, cell and drug icons

    Cell/gene therapy sector now sustainable; China competition mounting

    BioWorld
    There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
  • Dice spelling out D-E-A-L-?, yes, no

    Muted and missing M&As: JPM deals absent in 2026

    BioWorld
    For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing